Subscribe To
LOBEF / Lobe Sciences partner gets DEA quota to produce psilocin drug for two studies
LOBEF News
By Proactive Investors
September 18, 2023
Lobe Sciences appoints Mathew Lee as its next CFO
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has announced Mathew Lee as its new Chief Financial Officer. Lee is the president of Manning Lee Management more_horizontal
By Proactive Investors
September 15, 2023
Lobe Sciences announces amendment to Altemia acquisition agreement
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) told investors that it signed an amendment to its April 18, 2023, share purchase agreement to acquire Altemi more_horizontal
By Proactive Investors
July 3, 2023
Lobe Sciences provides further details regarding Altemia acquisition
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has provided further details regarding its acquisition of Altemia & Company LLC, first announced on April 1 more_horizontal
By Proactive Investors
June 27, 2023
Lobe Sciences commences Phase 1 clinical study to evaluate L-130
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has commenced a Phase 1 clinical study to evaluate L-130, their proprietary stabilized psilocin anal more_horizontal
By Proactive Investors
June 7, 2023
Lobe Sciences appoints Baxter Phillips III as chief operating officer
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has appointed Baxter Phillips III to the newly created position of chief operating officer (COO) eff more_horizontal
By Proactive Investors
May 17, 2023
Lobe Sciences names Pentec Health as exclusive US distributor of medical food Altemia for sickle cell disease
Lobe Sciences said it has entered into a commercial distribution agreement with Pentec Health for Altemia, a medical food with Lobe's proprietary form more_horizontal
By Proactive Investors
April 18, 2023
Lobe Sciences stock flies after its new acquisition spells revenue
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) stock shot up Tuesday after the biopharma company said it had inked a share purchase agreement to acquire Al more_horizontal
By Proactive Investors
April 18, 2023
Lobe Sciences boosts rare disease drug development portfolio with $3.8M acquisition
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) revealed that it has inked a share purchase agreement to acquire Altemia & Company LLC and all its assets, i more_horizontal